

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jiangsu Hengrui Pharmaceuticals Co., Ltd.**

**江蘇恒瑞醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1276)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange ([www.sse.com.cn](http://www.sse.com.cn)). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board  
**Jiangsu Hengrui Pharmaceuticals Co., Ltd.**  
江蘇恒瑞醫藥股份有限公司  
**Mr. Sun Piaoyang**  
*Chairman*

Shanghai, PRC  
March 13, 2026

*As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.*

# **Jiangsu Hengrui Pharmaceuticals Co., Ltd.**

## **Announcement in Relation to the Approval for Drug Registration**

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the “Company”), received a notice from the National Medical Products Administration (NMPA). The NMPA approves the Company’s self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets, for adding a new indication. The relevant information is hereby announced as follows:

### **I. Basic Information of the Drug**

Common name of drug: Hetrombopag Olamine Tablets

Dosage Form: Tablets

Strength: 2.5mg、 5mg

Registered Category: Class 2.4 chemical drug

Registration Acceptance No.: CXHS2400104, CXHS2400105

Prescription/Non-prescription Drug: Prescription Drug

Approved indications: This product, in combination with immunosuppressive therapy, is indicated for patients aged 15 years and older with treatment-naive severe aplastic anemia (SAA).

### **II. The Approved Indications of the Drug**

Hetrombopag Olamine Tablets were approved for marketing in 2021 for two

indications: 1. This product is indicated for the treatment of adult patients with chronic primary immune thrombocytopenia (ITP) who have had an insufficient response to glucocorticoids, immunoglobulins or other similar treatments. 2. This product is indicated for the treatment of adult patients with severe aplastic anemia (SAA) who have had an inadequate response to immunosuppressive therapy (IST).

### **III. Other Information of the Drug**

Aplastic anemia (AA) is a bone marrow failure (BMF) syndrome, which can be divided into two categories, SAA and non-severe AA (NSAA), according to the severity of the disease. Among them, SAA patients have rapid disease progression, a higher mortality rate due to infection or bleeding, with a poor expected outcome. Hetrombopag Olamine Tablets are an oral nonpeptide thrombopoietin receptor (TPO-R) agonist that promotes platelet production by activating TPO-R-mediated STAT and MAPK signaling pathways. Upon inquiry, it was found that similar products have been marketed in China and abroad, including Eltrombopag (brand name Promacta), Avatrombopag (brand name Doptelet) and Lusutrombopag (brand name Mupleta), and all three products have been approved for marketing in China. According to the EvaluatePharma database, the combined global sales of similar products in 2024 amounted to approximately USD 2.59 billion. As of now, the cumulative R&D investment for Hetrombopag Olamine Tablets related projects is approximately RMB 632.5 million (unaudited).

### **IV. Risk Warning**

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

March 13, 2026